Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7442086 | 0.98 | NPC1 (0.61) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| Trifluoroacetic Acid SCHEMBL7379290 | 0.90 | NPC1 (0.53) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| SCHEMBL7981993 | 0.89 | HDAC3 (0.64) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| SCHEMBL13314114 | 0.85 | NPC1 (0.59) | NPC1RAB9ALTA4HHDAC3NCOR2 | |
| SCHEMBL9800175 | 0.85 | NPC1 (0.62) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL906398 | 0.85 | RAB9A (0.62) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL13607002 | 0.85 | NPC1 (0.62) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL7424713 | 0.85 | NPC1 (0.62) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL6771205 | 0.83 | NPC1 (0.61) | NPC1RAB9AHDAC3NCOR2EGFR | |
| SCHEMBL9191952 | 0.83 | HDAC3 (0.71) | NPC1RAB9ALTA4HHDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| WO-2023168240-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2022056068-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | THE REGENTS OF THE UNIVERSITY OFCALIFORNIA (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3426638-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2020-05-06 | — | — | EP | disclosed |
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2019-02-21 | — | — | US | disclosed |
| EP-3426638-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Netherlands Translational Research Center B.V. (NL) | 2019-01-16 | — | — | EP | disclosed |
| CN-109071457-A | Inhibitors of indoleamine 2, 3-dioxygenase | 荷兰转化研究中心有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017153459-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-09-14 | — | — | WO | disclosed |
| CN-104379578-B | Carbamate compounds and its preparation and application | 阿比德治疗公司 | 2017-06-09 | — | — | CN | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567302-B2 | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| CN-104379578-A | Carbamate compounds and of making and using same | ABIDE THERAPEUTICS | 2015-02-25 | — | — | CN | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-6262040-B1 | Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | NPC1 1203/4885RAB9A 4077/4885LTA4H 2202/4885 |
| US-20190055213-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH2 | NPC1 1264/4885RAB9A 3505/4885LTA4H 1210/4885 |
| US-20150080364-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | CPS1, FABP4, VHL | NPC1 1062/4885RAB9A 2771/4885LTA4H 3143/4885 |
| US-20230365540-A1 | SMALL MOLECULE INHIBITORS OF ENPP1 | ENPP1, ENPP2, ENPP3 | NPC1 1815/4885RAB9A 534/4885LTA4H 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.